References
- Kim SC, Kim JH, Won JK, et al. Asymptomatic intrathyroidal pyriform sinus fistula mimicking thyroid cancer: a case report and literature review. Medicine (Baltimore). 2018;97:e0488.
- Fisher SB, Perrier ND. The incidental thyroid nodule. CA Cancer J Clin. 2018;68:97–105.
- Tiedje V, Stuschke M, Weber F, et al. Anaplastic thyroid carcinoma: review of treatment protocols. Endocr Relat Cancer. 2018;25:R153–R161.
- Roth MY, Witt RL, Steward DL. Molecular testing for thyroid nodules: review and current state. Cancer. 2018;124:888–898.
- Ren C, Liu Q, Wei Q, et al. Circulating miRNAs as potential biomarkers of age-related macular degeneration. Cell Physiol Biochem. 2017;41:1413–1423.
- Liu H, Lei C, He Q, et al. Nuclear functions of mammalian MicroRNAs in gene regulation, immunity and cancer. Mol Cancer. 2018;17:64.
- Curtale G. MiRNAs at the crossroads between innate immunity and cancer: focus on macrophages. Cells. 2018;7:pii: E12.
- Liu K, Zhao K, Wang L, et al. Prognostic value of microRNA-155 in human carcinomas: an updated meta-analysis. Clin Chim Acta Int J Clin Chem. 2018;479:171–180.
- Wang R, Ma Q, Ji L, et al. miR-622 suppresses tumor formation by directly targeting VEGFA in papillary thyroid carcinoma. Onco Targets Ther. 2018;11:1501–1509.
- Fang L, Kong D, Xu W. MicroRNA-625-3p promotes the proliferation, migration and invasion of thyroid cancer cells by up-regulating astrocyte elevated gene 1. Biomed Pharmacother. 2018;102:203–211.
- Yu L, Wu D, Gao H, et al. Clinical utility of a STAT3-regulated miRNA-200 family signature with prognostic potential in early gastric cancer. Clin Cancer Res. 2018;24:1459–1472.
- Wang Y, Xu YM, Zou YQ, et al. Identification of differential expressed PE exosomal miRNA in lung adenocarcinoma, tuberculosis, and other benign lesions. Medicine (Baltimore). 2017;96:e8361.
- Dong SJ, Cai XJ, Li SJ. The clinical significance of MiR-429 as a predictive biomarker in colorectal cancer patients receiving 5-fluorouracil treatment. Med Sci Monit. 2016;22:3352–3361.
- Zou J, Liu L, Wang Q, et al. Downregulation of miR-429 contributes to the development of drug resistance in epithelial ovarian cancer by targeting ZEB1. Am J Transl Res. 2017;9:1357–1368.
- Dong H, Hao X, Cui B, et al. MiR-429 suppresses glioblastoma multiforme by targeting SOX2. Cell Biochem Funct. 2017;35:260–268.
- Deng Y, Luan F, Zeng L, et al. MiR-429 suppresses the progression and metastasis of osteosarcoma by targeting ZEB1. EXCLI J. 2017;16:618–627.
- Yan XT, Zhao Y, Cheng XL, et al. Inhibition of miR-200b/miR-429 contributes to neuropathic pain development through targeting zinc finger E box binding protein-1. J Cell Physiol. 2018;233:4815–4824.
- Kong X, Ding X, Li X, et al. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer. Cancer Sci. 2015;106:982–989.
- Sheng N, Zhang L, Yang S. MicroRNA-429 decreases the invasion ability of gastric cancer cell line BGC-823 by downregulating the expression of heparanase. Exp Ther Med. 2018;15:1927–1933.
- Fan JY, Fan YJ, Wang XL, et al. miR-429 is involved in regulation of NF-κBactivity by targeting IKKβ and suppresses oncogenic activity in cervical cancer cells. FEBS Lett. 2017;591:118–128.
- Xue H, Tian GY. MiR-429 regulates the metastasis and EMT of HCC cells through targeting RAB23. Arch Biochem Biophys. 2018;637:48–55.
- Yang J, Liu Y, He A, et al. Hsa-miR-429 promotes bladder cancer cell proliferation via inhibiting CDKN2B. Oncotarget. 2017;8:68721–68729.
- Li D, Wang H, Song H, et al. The microRNAs miR-200b-3p and miR-429-5p target the LIMK1/CFL1 pathway to inhibit growth and motility of breast cancer cells. Oncotarget. 2017;8:85276–85289.
- Larsen JE, Nathan V, Osborne JK, et al. ZEB1 drive epithelial-to-mesenchymal transition in lung cancer. Clin Invest. 2016;9:3219–3235.
- Orellana-Serradell O, Herrera D, Castellon EA, et al. The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines. Asian J Androl. 2018;20:294–299.
- Chang YR, Park T, Park SH, et al. Prognostic significance of E-cadherin and ZEB1 expression in intraductal papillary mucinous neoplasm. Oncotarget. 2018;9:306–320.
- Orellana-Serradell O, Herrera D. Castellon EA and contreras HR: the transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines. Asian J Androl. 2017.